Pfizer (PFE) Short-term Investments (2009 - 2026)

Pfizer (PFE) has 18 years of Short-term Investments data on file, last reported at $11.4 billion in Q1 2026.

• Short-term Investments for Q1 2026 came in at $11.4 billion, down 28.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 billion (down 28.42% YoY), and the FY2025 annual result was $12.5 billion, down 35.92% from the prior year.
• Short-term Investments slipped to $11.4 billion in Q1 2026 per PFE's latest filing, from $12.5 billion in the prior quarter.
• Over five years, Short-term Investments peaked at $42.2 billion in Q3 2023 and troughed at $6.0 billion in Q2 2024.
• A 5-year average of $19.5 billion and a median of $15.9 billion in 2025 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 97.56% in 2024 and fell as far as 85.65% in 2024.
• A 5-year view of Short-term Investments shows it stood at $22.3 billion in 2022, then tumbled by 55.92% to $9.8 billion in 2023, then jumped by 97.56% to $19.4 billion in 2024, then slumped by 35.92% to $12.5 billion in 2025, then slipped by 8.69% to $11.4 billion in 2026.
• Business Quant data shows PFE's Short-term Investments at $11.4 billion in Q1 2026, $12.5 billion in Q4 2025, and $13.6 billion in Q3 2025.